GlassScriptPhysician profile
Christopher Damiano
NPI 1396199931
$3,793.07
in general payments reported to CMS, 2019-2025
27 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $32.30 · 2022: $704 · 2023: $1,024 · 2024: $583 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $795.32 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $434.52 | 2022-2023 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $337.62 | 2022-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Mylan Specialty L.P. | $281.93 | 2022-2024 | Yupelri |
| Viatris Specialty LLC | $241.89 | 2025 | Yupelri |
| Insmed, INC. | $187.09 | 2023-2025 | Arikayce |
| Harmony Biosciences LLC | $159.40 | 2023-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $157.24 | 2022-2024 | Dupixent |
| Abbvie INC. | $120.04 | 2025 | |
| Verona Pharma, INC. | $113.15 | 2025 | Ohtuvayre |
| Electromed, INC. | $109.98 | 2022-2024 | Smartvest |
| Janssen Pharmaceuticals, INC | $83.47 | 2022-2023 | Xarelto |
| Genzyme Corporation | $83.36 | 2023-2025 | |
| Pfizer INC. | $75.44 | 2019-2024 | |
| Philips North America LLC | $67.47 | 2022-2025 | Vest Therapy Und |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $67.46 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $62.39 | 2022-2023 | Acthar |
| Becton, Dickinson and Company | $58.23 | 2019 | |
| Baxter Healthcare | $52.74 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
| Amgen INC. | $47.67 | 2024-2025 | Tezspire |
| Genentech USA, INC. | $47.21 | 2024-2025 | Xolair |
| United Therapeutics Corporation | $42.00 | 2023-2024 | Tyvaso |
| Inogen, INC. | $33.72 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| E.R. Squibb & Sons, L.L.C. | $33.54 | 2019-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $30.45 | 2025 | Aralast |
| Kaleo, INC. | $20.49 | 2019 | |
| Pulmonx Corporation | $16.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Damiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.